講座・研究室 腎臓内科学講座【腎臓内科学】

教室紹介 研究 スタッフ紹介 業績・主な著書・論文 募集

ようこそ、腎臓内科学へ
診療科のホームページもご覧下さい

附属病院内の腎臓内科：順天堂医院｜静岡病院｜浦安病院｜東京江東高齢者医療センター｜練馬病院

教室紹介

順天堂大学腎臓内科学講座は、1969年の臓器別講座導入に伴い開設され、長年にわたり腎疾患の診療・研究・教育に取り組んできました。現在は鈴木祐介主任教授のもと、腎炎・ネフローゼ、慢性腎臓病（CKD）、糖尿病関連腎臓病、高血圧、急性腎障害（AKI）、腎代替療法など、腎臓病学の幅広い領域を対象として診療・研究を行っています。

私たちが大切にしているのは、日々の診療から生まれる疑問を研究につなげ、その成果を再び患者さんの診療へ還元することです。腎臓病は、免疫、代謝、循環、加齢、腸内細菌叢など多様な因子が複雑に関与して発症・進展します。当教室では、患者検体を用いた臨床研究と、細胞・動物モデルを用いた基礎研究を組み合わせることで、腎疾患の病態を理解し、新しい診断法・治療法につなげるトランスレーショナルリサーチを推進しています。

国内外の研究機関や順天堂大学内の各研究部門とも連携し、若手医師・大学院生が臨床上の疑問を自ら研究テーマとして発展させ、成果を発信できる研究環境の構築を目指しています。

zinzo_2609_01

高雄順天堂カンファレンス（国際共同研究発表会）

研究

1．IgA腎症・糸球体疾患

IgA腎症は、当教室が長年にわたり取り組んできた中心的な研究テーマの一つです。

IgA腎症を、腎臓だけではなく粘膜免疫と全身免疫の異常が関与する疾患として捉え、上気道・腸管などの粘膜免疫、自然免疫、B細胞・形質細胞、糖鎖異常IgA、補体などの観点から病態解明を進めています。

特に、粘膜での免疫応答がどのように異常IgAの産生につながり、IgAが腎臓に沈着する機序、どのような炎症や組織障害を引き起こすのかについて研究しています。また、腎生検組織や血液・尿を用いて、疾患活動性や予後を反映するバイオマーカー、新たな治療標的の探索にも取り組んでいます。

IgA腎症以外にも、ネフローゼ症候群、半月体形成性糸球体腎炎など、さまざまな糸球体疾患について、その発症・進展機序や治療反応性に関する研究を行っています。

 

2．糖尿病関連腎臓病・慢性腎臓病

糖尿病関連腎臓病（DKD）および慢性腎臓病（CKD）の代表的な原因疾患の１つです。当研究では、DKDをはじめとするCKDの発症・進展機序を明らかにし、腎機能低下を予測する新たな方法や治療法の開発につなげる研究を行っています。

腎障害には、糖代謝異常だけでなく、炎症、酸化ストレス、終末糖化産物（AGEs）、腸内細菌叢、栄養、生活環境、心腎連関など、さまざまな因子が複雑に関与しています。これらの因子が腎障害の発症・進展に及ぼす影響を多角的に解析するとともに、血液・尿中の新規バイオマーカーを探索し、CKDの早期診断や腎予後予測への応用を目指しています。

さらに、基礎研究で得られた知見と患者さんの臨床データを組み合わせることで、DKD・CKDの多様な病態を明らかにし、個々の患者さんの病態に応じた、より適切な治療につなげることを目標としています。

 

3．高血圧・心腎連関

腎臓は血圧調節に重要な役割を担う一方、高血圧そのものが腎障害を進展させます。当教室では、レニン・アンジオテンシン・アルドステロン系（RAAS）をはじめとする血圧調節機構と腎障害との関連について研究しています。

また、心臓と腎臓が相互に影響を及ぼす「心腎連関」に着目し、高血圧、CKD、心血管疾患を一連の病態として捉えた研究を進めています。新たな降圧薬・心不全治療薬が腎機能や蛋白尿、心血管系に与える影響についても検討しています。

 

4．AKI・尿細管間質障害

急性腎障害（AKI）および尿細管間質障害の発症・進展機序について、炎症、自然免疫、酸化ストレス、虚血、細胞障害などの観点から研究を行っています。

さらに、薬剤や健康食品・サプリメントなどによる腎障害についても、臨床所見と腎病理所見を組み合わせて病態を解析しています。AKIからCKDへの移行機序についても重要な研究課題として取り組んでいます。

 

5．腎代替療法・透析

血液透析・腹膜透析を含む腎代替療法について、患者さんの生命予後とQOLの向上を目指した臨床研究を行っています。

透析患者における心血管合併症、体液・血圧管理、バスキュラーアクセス、感染症など、日常診療に直結するさまざまな課題を研究対象としています。

腹膜透析については、腹膜機能の維持、カテーテル・出口部管理、感染予防、残存腎機能の保持など、安全で長期的な治療継続につながる研究を進めています。

教授

経歴
平成2年順天堂大学医学部卒業
専門分野
IgA腎症、高血圧

鈴木 祐介（すずき ゆうすけ）

医学部・大学院医学研究科：主任教授
順天堂医院：腎・高血圧内科

y_suzuki_211011

経歴
平成6年順天堂大学医学部卒業
専門分野
糖尿病関連腎臓病

合田 朋仁（ごうだ ともひと）

医学部・大学院医学研究科：教授
順天堂医院：腎・高血圧内科

経歴
平成4年山形大学医学部卒業
専門分野
ネフローゼ症候群

清水 芳男（しみず よしお）

医学部・大学院医学研究科：教授
静岡病院：腎臓内科　科長

shimizu

経歴
平成6年順天堂大学医学部卒業
専門分野
腎不全、透析療法

井尾 浩章（いお ひろあきろ）

医学部・大学院医学研究科：教授
練馬病院：腎・高血圧内科

経歴
平成8年順天堂大学医学部卒業
専門分野
IgA腎症

鈴木 仁（すずき　ひとし）

医学部・大学院医学研究科：教授
浦安病院：腎・高血圧内科

先任准教授

経歴
平成10年順天堂大学医学部卒業
専門分野
慢性腎臓病、腎代替療法

中田 純一郎（なかた じゅんいちろう）

医学部・大学院医学研究科：先任准教授
順天堂江東高齢者医療センター：腎・高血圧内科　科長

准教授

経歴
平成12年順天堂大学医学部卒業
専門分野
ネフローゼ症候群、電解質異常、多発性嚢胞腎

木原 正夫（きはら まさお）

医学部・大学院医学研究科：准教授
順天堂医院：腎・高血圧内科 医局長

経歴
平成12年順天堂大学医学部卒業
専門分野
IgA腎症

山田 耕嗣（やまだ こうし）

医学部・大学院医学研究科：准教授
順天堂医院：腎・高血圧内科

経歴
平成13年順天堂大学医学部卒業
専門分野
糖尿病関連腎臓病、高血圧

村越 真紀（むらこし まき）

医学部・大学院医学研究科：准教授
順天堂医院：腎・高血圧内科　外来医長

経歴
平成14年帝京大学医学部卒業
専門分野
高血圧、遺伝性血管性浮腫

小林 敬（こばやし たかし）

医学部・大学院医学研究科：准教授
順天堂医院：腎・高血圧内科　病棟医長

経歴
平成9年順天堂大学医学部卒業
専門分野
腎臓病（全般）

髙原 久嗣（たかはら ひさつぐ）

医学部・大学院医学研究科：准教授
浦安病院：腎・高血圧内科　医局長




当教室員が参加している主な国内・国際学会

国内学会
  • 日本内科学会
  • 日本腎臓学会
  • 日本透析医学会
  • 日本腹膜透析医学会
  • 日本高血圧学会
  • 日本妊娠高血圧学会
  • 日本成人病（生活習慣病）学会
  • 日本免疫学会
  • 日本糖尿病学会

 

国際学会
  • American Society of Nephrology（ASN）
  • International Society of Nephrology（ISN）
  • European Renal Association（ERA）
  • Asian Pacific Society of Nephrology (APSN)

 

当教室では、国内外の主要な関連学会に積極的に参加し、日々の診療や研究から得られた成果を発表しています。また、国際学会での発表や研究交流を通じて、最新の知見を共有するとともに、世界に向けた研究成果の発信にも取り組んでいます。

2026年 英文原著
  • Kataoka H, Manabe S, Moriyama T, Ushio Y, Nitta K, Hoshino J, Hirano K, Matsuzaki K, Yasuda T, Yasuda Y, Kawamura T, Maruyama S, Yokoo T, Suzuki Y: Attribute-Based Medicine for IgA Nephropathy: Risk Factor Constellations Influence Kidney Prognosis. Nephrol Dial Transplant. 2026; 41(2): 353-366.
  • Fukao Y, Suzuki H, Nihei Y, Makita Y, Kano T, Nakayama M, Lee M, Kato R, Kihara M, Suzuki Y.: Plasmacytoid dendritic cells modulate the production of mucosal IgA in IgA nephropathy. Nephrol Dial Transplant. 2026; 41(5): 888-897.
  • Kuo JJ, Wu J, Gunawan MG, McConnell MT, Lester J, Naidu NA, Nieh CH, Surendradoss J, Kano T, Suzuki Y, Olson NE, Cox JH.: Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in Immunoglobulin A Nephropathy. Kidney360. 2026; 7(5): 1003-1016.
  • Yamada K, Ogiwara K, Novak J, Suzuki Y: Aberrant signaling in tonsillar B cells producing pathogenic O-glycoforms of IgA1 in IgA nephropathy. Front Immunol. 2026; 17: 1737992.
  • Kataoka H, Manabe S, Moriyama T, Ushio Y, Nitta K, Hoshino J, Hirano K, Matsuzaki K, Yasuda T, Yasuda Y, Kawamura T, Maruyama S, Yokoo T, Suzuki Y: Attribute-based medicine for IgA nephropathy: risk factor constellations influence kidney prognosis. Nephrol Dial Transplant. 2026; 41(2): 353-366.
  • Koshida T, Nittono H, Takei H, Murakoshi M, Yamashiro Y, Suzuki Y, Gohda T: A Comprehensive Analysis of Serum and Urine Bile Acid Profiles in Chronic Kidney Disease: An Exploratory Study of Clinical Associations. Nephrology (Carlton）. 2026; 31(1): e70156.
  • Sakuma H, Murakoshi M, Hagiwara S, Shibata T, Suzuki Y, Gohda T: Effects of Progranulin deficiency on inflammation and fibrosis in thekidney and liver of diabetic fed a high-fat diet. Endocrinol Metab (Seoul). 2026; 41(1): 138-151.
  • Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong M　G, Barratt J, Suzuki Y, Liew A, Zhang H, Carroll K, Jha V, Quevedo A, Han S H, Praga M, Chacko B, Sahay M, Cheung C K, Kooienga L, Walsh M, Xia J, Fajardo C, Shah L, Hafkin J, Rizk D V; VISIONARY Trial Investigators Group: Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. N Eng J Med. 2026; 394(7): 635-646.
  • Sakaguchi R, Joh K, Honma S, Shimizu A, Hashiguchi A, Katafuchi R, Nishikawa M, Koike K, Hirano K, Tsuboi N, Kawamura T, Yokoo T, Suzuki Y: Comparison of Oxford versus Japanese Histological Grading to predict renal function decline in IgA nephropathy: a Japanese prospective cohort study. Sci Rep. 2026; 16(1): 6995.
  • 10. Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, Sanuki M, Tomino Y, Suzuki Y, Murakoshi M: Refining the Cardiovascular–Kidney–Metabolic Staging System for Improved Risk Stratification of Chronic Kidney Disease Progression in Type 2 Diabetes. Circ Rep. 2026; 8(5): 848-856.
  • Sasaki T, Tsuboi N, Koike K, Ueda H, Okabe M, Yokote S, Shimizu A, Hirano K, Kawamura T, Yokoo T, Suzuki Y; The J-IGACS working group: Initial proteinuria reduction and advere kidney outcomes in IgA nephropathy: an analysis from the J‑IGACS. Clin Exp Nephrol. 2026; 30(2): 331-338.
  • Yano Y, Nagasu H, Kanegae H, Itano S, Nangaku M, Suzuki H, Ohashi M, Okada H, Suzuki Y, Kashihara N: Association between early proteinuria reduction and kidney outcomes in Japanese patients with IgA nephropathy: The Japan Chronic Kidney Disease Database. Clin Exp Nephrol. 2026; 30(3): 424-433
  • Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, Tang SCW, Trimarchi H, Floege J: Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney Int. 2026; 110(3): 502-507
  • Iwasaki H, Nihei Y, Suzuki H, Kitamura D and Suzuki Y: Serum anti-β2 spectrin IgA antibodies are produced in a CD4 T cell independent manner in IgA nephropathy model mouse. Front Immunol. 2026; 17: 1696625.
  • Murakoshi M, Kamei N, Tanaka M, Sato T, Furuhashi M, Kubota M, Sanuki M, Suzuki Y, Gohda T: High-normal levels of B-type natriuretic peptide are associated with chronic kidney disease progression independent of albuminuria in individuals with diabetes: an observational cohort study. Diabetes Res Clin Pract. 2026; 235: 113192.
2025年 英文原著
  • Usui N, Nakata J, Uehata A, Kojima S, Hisadome H, Inatsu A, Tsubaki A, Saitoh M, Ando S, Kitayama T, Maikusa K, Nishiyama Y, Suzuki Y.: Determinants of Longitudinal Changes in Exercise Capacity in Patients with Independent Functioning on Hemodialysis. Phys Ther. 2025; 105(1): pzae147.
  • Barbour SJ, Coppo R, Barratt J, Er L, Lafayette R, Heerspink HJL, Rizk DV, Liew A, Jha V, Zhang H, Suzuki Y, Trimarchi H, Cattran DC; International IgA Nephropathy Network Research Group.: Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts. Kidney Int Rep. 2025; 10(4): 1283-1287.
  • Otsuka T, Ueda S, Yamagishi SI, Nagasawa H, Okuma T, Wakabayashi K, Kobayashi T, Murakoshi M, Nakata M, Gohda T, Matsui T, Higashimoto Y, Suzuki Y.: Involvement of Mineralocorticoid Receptor Activation by High Mobility Group Box 1 and Receptor for Advanced Glycation End Products in the Development of Acute Kidney Injury. Kidney360. 2025; 6(2): 208-218.
  • Koshida T, Gohda T, Kaga N, Taka H, Shimozawa K, Murakoshi M, Yamashiro Y, Suzuki Y.: Inappropriate diet and hygiene status affect the progression of diabetic kidney disease by causing dysbiosis. Nutrition. 2025; 131: 112633.
  • Koizumi A, Nihei Y, Mori K, Aoki R, Suzuki H, Barratt J, Suzuki Y.: The prevalence and characteristics of IgA antibodies to β2-spectrin and CBX3 in IgA nephropathy. Kidney Int Rep. 2025; 10(5): 1486-1494.
  • Ikeda A, Peng G, Zhao W, Abudouwanli A, Ikeda S, Niyonsaba F, Suzuki Y.: Impact of atopic dermatitis on renal dysfunction: Insights from patient data and animal models. Front Immunol. 2025; 16: 1558596.
  • Kojima S, Usui N, Uehata A, Inatsu A, Chiba Y, Hisadome H, Suzuki Y, Nakata J, Tsubaki A.: Acute effect of moderate-intensity interval intradialytic exercise on cerebral oxygenation in hemodialysis patients: A randomized crossover trial. J Am Soc Nephrol. 2025; 36(9): 1811-1822.
  • Usui N, Nakata J, Uehata A, Kojima S, Ando S, Saitoh M, Inatsu A, Hisadome H, Nishiyama Y, Suzuki Y.: Association of Physiological Reserve Obtained from Cardiopulmonary Exercise Testing and Frailty with All-Cause Mortality in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2025; 20(3): 420-431.
  • Tanaka M, Sato T, Gohda T, Kamei N, Murakoshi M, Ishiwata E, Endo K, Kawaharata W, Aida H, Nakata K, Akiyama Y, Kubota M, Sanuki M, Suzuki T, Suzuki Y, Furuhashi M.: Elevated urinary fatty acid-binding protein 4 level predicts future renal dysfunction and poor prognosis in Japanese patients with diabetes: a longitudinal cohort study. Clin Kidney J. 2025; 18(4): sfaf056.
  • 10. Tanaka M, Sato T, Gohda T, Kamei N, Murakoshi M, Ishiwata E, Endo K, Kawaharata W, Aida H, Nakata K, Akiyama Y, Kubota M, Sanuki M, Suzuki T, Suzuki Y, Furuhashi M.: Urinary fatty acid-binding protein 4 is a promising biomarker for glomerular damage in patients with diabetes mellitus. J Diabetes Investig. 2025; 16(4): 670-679.
  • Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T.: Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease. J Clin Hypertens. 2025; 27(7): e70089.
  • Hagiwara S, Okabe J, Ziemann M, Drew B, Murakoshi M, Sourris KC, McClelland AD, Bose M, Ekinci EI, Coughlan MT, Laskowski A, Sakuma H, Gohda T, Suzuki Y, Cooper ME, Kantharidis P.: miR-214 and Its Primary Transcript Dnm3os Regulate Fibrosis and Inflammation Through RAGE Signaling in Diabetic Kidney Disease. Diabetes. 2025; 74(7): 1205-1219.
  • Hirano K, Ikenoue T, Seki T, Komukai S, Nakata H, Yasuda T, Yasuda Y, Matsuzaki K, Kawamura T, Yokoo T, Maruyama S, Suzuki H, Suzuki Y, Fukuma S.: Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study. J Nephrol. 2025; 38(6): 1573-1582.
  • Kashihara N, Okada H, Suzuki Y, Iwamoto T, Yasutomi M, Matsui M, Takezawa R, Ishii T, Tomioka Y.: Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study. Clin Exp Nephrol. 2025; 29(7): 899-911.
  • Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, Sanuki M, Mikami R, Mizutani K, Suzuki Y, Murakoshi M.: Association of the Glycated Albumin-to-Glycated Haemoglobin Ratio With Mortality in Type 2 Diabetes: A Retrospective Cohort Analysis. Endocrinol Diabetes Metab. 2025; 8(4): e70072.
  • Maeda T, Nakata J, Nojiri S, Kano T, Fukuzaki H, Suzuki K, Io H, Suzuki Y.: Radial artery calcification is a predictor of aortic stenosis development and progression after initiation of hemodialysis. Sci Rep. 2025; 15(1): 30350.
  • Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, Sanuki M, Koshida T, Hagiwara S, Suzuki Y, Murakoshi M.: Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF-15 With Adverse Outcomes in Diabetes Mellitus. J Cachexia Sarcopenia Muscle. 2025; 16(4): e70011.
  • Gohda T, Kamei N, Tanaka M, Furuhashi M, Sato T, Kubota M, Sanuki M, Mikami R, Mizutani K, Suzuki Y, Murakoshi M.: Independent predictive role of nutritional markers in kidney function decline and mortality in diabetes. Metabol Open. 2025; 27: 100386.
  • Watanabe S, Nakayama M, Yokoo T, Sanada S, Ubara Y, Komatsuda A, Asanuma K, Suzuki Y, et al.; LUBI-CKD TRIAL Investigators.: Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial. Sci Adv. 2025; 11(35): eadw3934.
  • Nihei Y, Aoki R, Matsuzaki K, Koizumi A, Saeki H, Sakai I, Kihara M, Yao T, Suzuki Y.: Glomerular Galactose-Deficient IgA1 Deposition in 192 Autopsy Cases in Japan. Nephrology (Carlton). 2025; 30(9): e70128.
  • Koshida T, Suzuki H, Murakoshi M, Takahara H, Suzuki Y, Gohda T.: Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: a multicenter prospective study. J Int Med Res. 2025; 53(9): 3000605251376895.
  • Nakayama M, Suzuki H, Fukao Y, Nihei Y, Suzuki Y.: Thymic stromal lymphopoietin may induce steroid resistance in minimal change disease. Nephrology (Carlton). 2025; 30(9): e70123.
  • Okamoto I, Oji K, Nakashima O, Shu Y, Takahara H, Suzuki H, Muguruma H.: Elucidation of the mechanism of precipitate formation on mixing nafamostat mesilate solution with dialysate. J Artif Organs. 2025; 28(3): 423-430.
  • Kadota N, Fujimaru T, Takahashi O, Konishi K, Ito Y, Nagahama M, Taki F, Suzuki M, Nakayama M.: Risk factors for unexpected clinical deterioration in hospitalized patients undergoing maintenance hemodialysis. Clin Exp Nephrol. 2025; 29(9): 1271-1278.
  • Murakoshi M, Kamei N, Abe K, Iwasawa T, Kato K, Tanaka M, Sato T, Furuhashi M, Kubota M, Sanuki M, Suzuki Y, Gohda T.: Association among circulating erythropoietin-producing hepatoma A2, progranulin, and kidney function in individuals with diabetes. J Diabetes Investig. 2025; 16(10): 1836-1843.
  • Kim JS, Suzuki H, Fukao Y, Kano T, Nakayama M, Nihei Y, Suzuki Y.: B Cell Activating Factor Does Not Play a Pivotal Role in the Synthesis of Aberrantly Glycosylated IgA. Nephrology (Carlton). 2025; 30(10): e70139.
  • Sato E, Kagiyama N, Kasai T, Morito K, Nakajima Y, Ito Y, Dotare T, Sunayama T, Kaneko T, Sato A, Iso T, Murata A, Kato T, Suda S, Nohara N, Nakata J, Minamino T, Suzuki Y, Daida H.: Video-Based Automatic Quantification of Leg Edema: a Pilot Study in Patients With Hemodialysis With and Without Heart Failure – Proof-of-Concept Study. Circ Rep. 2025; 8(1): 162-164.
  • Perkovic V, Barratt J, Lafayette R, Liew A, Suzuki Y, Carroll K, Cheung CK, Tesař V, Trimarchi H, Wong MG, Zhang H, Xia J, Fajardo C, Shah L, Hafkin J, Rizk DV.: Evaluating Sibeprenlimab in IgA Nephropathy – Rationale and Baseline Data from the VISIONARY Trial. Kidney Int Rep. 2025; 10(12): 4207-4218.
  • Kishida C, Murakoshi M, Sakuma H, Shibata T, Suzuki Y, Gohda T.: Effect of tofogliflozin on skeletal muscle mitochondrial function in male diabetic mice with muscle atrophy. J Endocr Soc. 2025; 10(2): bbaf171.
  • Nishizawa K, Tanaka M, Sato T, Gohda T, Kamei N, Murakoshi M, Akiyama Y, Kawaharata W, Aida H, Kouzu H, Yama N, Kubota M, Sanuki M, Suzuki Y, Furuhashi M.: The health stage of cardiovascular-kidney-metabolic (CKM) syndrome is useful for predicting all-cause mortality in patients with type 2 diabetes: a cohort study in a period prior to the standard use of recent pharmacotherapy. J Diabetes Complications. 2025; 39(10): 109146.
  • Nakata J, Fukuzaki H, Maeda T, Suzuki K, Kano T, Nohara N, Io H, Suzuki Y.: Examination of the Concordance Between Healthcare Professionals' and the Patient's Own Assessment of the Peritoneal Dialysis Catheter Exit Site. Ther Apher Dial. 2025; 29(6): 898-904.
  • Okuma T, Nagasawa H, Otsuka T, Masutomi H, Matsushita S, Suzuki Y, Ueda S.: Fruits granola consumption may contribute to a reduced risk of cardiovascular disease and urinary tubular dysfunction in patients with chronic kidney disease of stage G2-4. Foods. 2025; 14(24): 4346.
  • Floege J, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, Tang SCE, Trimarchi H, Balk EM, Gordon CE, Adam GP, Tonelli MA, Earley A, Rovin BH: Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025; 108(4): 548-554
  • Kano T, Io H, Sasaki Y, Muto M, Muto S, Ogiwara K, Ikeda A, Iwasaki H, Suzuki Y: A case of atypical hemolytic uremic syndrome with a complement factor I mutation triggered by a femoral neck fracture. Nephrology (Carlton). 2025; 30(3): e70010.
  • Sasaki T, Tsuboi N, Yokote S, Koike K, Shimizu A, Hirano K, Ueda H, Okabe M, Kawamura T, Yokoo T, Suzuki Y; on behalf of the J-IGACS Working Group: Supportive Evidence of Surrogate End Points Based on Treatment Effect of Corticosteroid in IgA Nephropathy. Kidney Int Rep. 2025; 11(2): 103588.
  • Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group; Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, Tang SCW, Trimarch H, Floege J: KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025; 108(4S): S1-S71.
2024年 英文原著
  • Yano Y, Nishiyama A, Suzuki Y, Morimoto S, Morikawa T, Gohda T, Kanegae H, Nakashima N.: Relevance of ChatGPT’s responses to common hypertension-related patient inquiries. Hypertension. 2024; 81(1): e1-e4.
  • Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group.: A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024; 390(1): 20-31.
  • Yamada K, Novak J, Suzuki Y.: GWAS-follow-up studies identified a connection between abnormal LIF/JAK2/STAT1 signaling and overproduction of galactose-deficient IgA1 in the tonsillar IgA1-secreting cells from patients with IgA nephropathy. J Clin Res Bioeth. 2024; 15(1): 478.
  • Yamada K, Huang ZQ, Reily C, Green TJ, Suzuki H, Novak J, Suzuki Y.: LIF/JAK2/STAT1 signaling enhances production of galactose-deficient IgA1 by IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy. Kidney Int Rep. 2024; 9(2): 423-435.
  • Adachi E, Murakoshi M, Shibata T, Shimozawa K, Sakuma H, Kishida C, Gohda T, Suzuki Y.: Progranulin deficiency attenuates tubulointerstitial injury in a mouse unilateral ureteral obstruction model. Exp Anim. 2024; 73(3): 293-301.
  • Nagasawa H, Ueda S, Suzuki H, Jenkinson C, Fukao Y, Nakayama M, Otsuka T, Okuma T, Clapper W, Liu K, Nguyen M, Komers R, Suzuki Y.: Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nephrol Dial Transplant. 2024; 39(9): 1494-1503.
  • Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Wada J, Sugiyama H, Nakano T, Wada T, Shimizu M, Suzuki H, Komatsu H, Nakashima N, Kitaoka K, Narita I, Okada H, Suzuki Y, Kashihara N.: Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database. Nephrology (Carlton). 2024; 29(2): 65-75.
  • Wimbury D, Muto M, Bhachu JS, Scionti K, Brown J, Molyneux K, Seikrit K, Maixnerova D, Perez-Alos L, Garred P, Floege J, Tesar V, Fellstrom B, Coppo R, Barratt J.: Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial. Kidney Int. 2024; 105(2): 381-388.
  • Usui N, Nakata J, Uehata A, Kojima S, Saitoh M, Chiba Y, Ando S, Inatsu A, Hisadome H, Ota S, Suzuki Y.: Comparison of intradialytic continuous and interval training on hemodynamics and dialysis adequacy: A crossover randomized controlled trial. Nephrology (Carlton). 2024; 29(4): 214-221.
  • 10. Barbour SJ, Coppo R, Er L, Pillebout E, Russo ML, Alpers CE, Fogo AB, Ferrario F, Jennette JC, Roberts ISD, Cook HT, Ding J, Su B, Zhong X, Fervenza FC, et al.: Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis. Clin J Am Soc Nephrol. 2024; 19(4): 438-451.
  • Gohda T, Murakoshi M, Shibata T, Suzuki Y, Takemura H, Tsuchiya K, Okada T, Wakita M, Horiuchi Y, Tabe Y, Kamei N.: Circulating TNF receptor levels are associated with estimated glomerular filtration rate even in healthy individuals with normal kidney function. Sci Rep. 2024; 14(1): 7245.
  • Ariyasu Y, Torikoshi K, Tsukamoto T, Yasuda T, Yasuda Y, Matsuzaki K, Hirano K, Kawamura T, Yokoo T, Maruyama S, Suzuki Y, Muso E.: Analysis of the impact of obesity on the prognosis of IgA nephropathy according to renal function and sex. Clin Exp Nephrol. 2024; 28(11): 1155-1167.
  • Aoki R, Nihei Y, Matsuzaki K, Suzuki H, Kihara M, Ogawa A, Nishino T, Sanada S, Yokote S, Okabe M, Shirai S, Fukuda A, Hoshino J, Kondo D, Yokoo T, Kashihara N, Narita I, Suzuki Y.: Gross hematuria after the COVID-19 mRNA vaccination: Nationwide multicenter prospective cohort study in Japan. Kidney360. 2024; 5(9): 1322-1332.
  • Usui N, Nakata J, Uehata A, Kojima S, Hisadome H, Ando S, Saitoh M, Inatsu A, Tsuchiya T, Mawatari T, Suzuki Y.: Association of postexercise vagal dysfunction with protein-energy wasting and noncardiovascular outcomes in patients receiving hemodialysis: A retrospective cohort study. J Ren Nutr. 2024; 34(4): 321-329.
  • Kojima S, Usui N, Shigetake M, Uehata A, Inatsu A, Ando S, Matsuzawa R, Suzuki Y, Nakata J, Tsuchiya T, Hisadome H, Mawatari T, Tsubaki A.: Intramuscular and abdominal fat measured by computed tomography and mortality of hemodialysis patients. Nephrol Dial Transplant. 2024; 39(2): 286-296.
  • Tanaka M, Gohda T, Kamei N, Murakoshi M, Sato T, Kubota M, Sanuki M, Ishiwata E, Endo K, Suzuki Y, Furuhashi M.: Associations between circulating levels of FABP4 and TNF receptors are more evident in patients with type 2 diabetes mellitus than in patients with type 1 diabetes mellitus. Endocr Connect. 2024; 13(11): e240343.
  • Gohda T, Murakoshi M, Suzuki Y, Kagimura T, Wada T, Narita I.: Effect of proteinuria on the rapid kidney function decline in chronic kidney disease depends on the underlying disease: A post hoc analysis of the BRIGHTEN study. Diabetes Res Clin Pract. 2024; 212: 111682.
  • Mikami R, Mizutani K, Ishimaru M, Gohda T, Iwata T, Aida J.: Preventive dental care reduces risk of cardiovascular disease and pneumonia in hemodialysis population: A nationwide claim database analysis. Sci Rep. 2024; 14(1): 12372.
  • Suzuki Y, Kaneko H, Nagasawa H, Okada A, Fujiu K, Jo T, Takeda N, Morita H, Nishiyama A, Gohda T, Suzuki Y, Node K, Yasunaga H, Nangaku M, Komuro I.: Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study. Diabetes Obes Metab. 2024; 26(6): 2422-2430.
  • Nagasawa H, Suzuki S, Kobayashi T, Otsuka T, Okuma T, Matsushita S, Amano A, Shimizu Y, Suzuki Y, Ueda S.: Effect of fruits granola (Frugra®) consumption on blood pressure reduction and intestinal microbiome in patients undergoing hemodialysis. Hypertens Res. 2024; 47: 3214-3224.
  • Nagasawa H, Kaneko H, Suzuki Y, Okada A, Fujiu K, Takeda N, Morita H, Nishiyama A, Yano Y, Node K, Viera AJ, Carey RM, Oparil S, Yasunaga H, Touyz RM, Komuro I.: Association of cancer with the risk of developing hypertension. Eur Heart J Qual Care Clin Outcomes. 2024; 10(3): 228-234.
2023年 英文原著
  • Yokote S, Ueda H, Shimizu A, Okabe M, Haruhara K, Sasaki T, Aoki R, Joh K, Saeki H, Tomita S, Tsuboi N, Suzuki H, Suzuki Y, Yokoo T.: First diagnosis of immunoglobulin A nephropathy following SARS-CoV-2 mRNA vaccination in Japan. Kidney Int Rep. 2023; 8: 179-182.
  • Shirai S, Yasuda T, Kumagai H, Matsunobu H, Ichikawa D, Shibagaki Y, Yasuda Y, Matsuzaki K, Hirano K, Kawamura T, Suzuki Y, Maruyama S.: Prognostic factors of IgA nephropathy presenting with mild proteinuria at the time of diagnosis: a multicenter cohort study. Clin Exp Nephrol. 2023; 27: 340-348.
  • Shioda R, Jo-Watanabe A, Okuno T, Saeki K, Nakayama M, Suzuki Y, Yokomizo T.: The leukotriene B4/BLT1-dependent neutrophil accumulation exacerbates immune complex-mediated glomerulonephritis. FASEB J. 2023; 37(2): e22789.
  • Iwasaki M, Suzuki H, Umezawa Y, Koshida T, Saito M, Fukuda H, Takahara H, Matsuzaki K, Suzuki Y.: Efficacy and safety of pemafibrate in patients with chronic kidney disease: a retrospective study. Medicine (Baltimore). 2023; 102(7): e32818.
  • Misaki T, Naka S, Suzuki H, Li M, Aoki R, Nagasawa Y, Matsuoka D, Ito S, Nomura R, Nakano MM, Suzuki Y, Nakano K.: cnm-positive Streptococcus mutans is associated with galactose-deficient IgA in patients with IgA nephropathy. PLoS One. 2023; 18(3): e0282367.
  • Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer IM, Aygören-Pürsün E, Ritchie B, Sussman GL, Anderson J, Kawahata K, Suzuki Y, Staubach P, Treudler R, Feuersenger H, Glassman F, Jacobs I, Magerl M.: Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10382): 1079-1090.
  • Sofue T, Oguchi H, Yazawa M, Tsujita M, Futamura K, Nishihira M, Toyoda M, Kano T, Suzuki H.: Serological and histopathological assessment of galactose-deficient immunoglobulin A1 deposition in kidney allografts: a multicenter prospective observational study. PLoS One. 2023; 18(2): e0281945.
  • Fukuzaki H, Nakata J, Nojiri S, Shimizu Y, Shirotani Y, Maeda T, Kano T, Mishiro M, Nohara N, Io H, Suzuki Y.: Outpatient clinic specific for end-stage renal disease improves patient survival rate after initiating dialysis. Sci Rep. 2023; 13: 5991.
  • Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura M, Suzuki Y, Kitamura D.: Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv. 2023; 9: 1-12.
  • 10. Kiryluk K, et al., Suzuki H, Gharavi AG.: Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023; 55(7): 1091-1105.
  • Koshida T, Gohda T, Sugimoto T, Asahara T, Asao R, Ohsawa I, Gotoh H, Murakoshi M, Suzuki Y, Yamashiro Y.: Gut microbiome and microbiome-derived metabolites in patients with end-stage kidney disease. Int J Mol Sci. 2023; 24: 11456.
  • Nangaku M, Kitching AR, Boor P, Fornoni A, Floege J, Coates PT, Himmelfarb J, Lennon R, Anders HJ, Humphreys BD, Caskey FJ, Fogo AB, and the TRANSFORM group: International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. Kidney Int. 2023; 104: 36-45.
  • Maeda T, Io H, Hara K, Nakata J, Ishizaka M, Shimizu Y, Shirotani Y, Fukuzaki H, Suzuki Y.: Laparoscopic observations of adhesions between peritoneal dialysis catheters and intraperitoneal organs: a retrospective observational study. Nephrology (Carlton). 2023; 28(12): 684-687.
  • Matsuzaki K, Suzuki H, Kikuchi M, Koike K, Komatsu H, Takahashi K, Narita I, Okada H; Committee of Clinical Practical Guideline for IgA Nephropathy 2020.: Current treatment status of IgA nephropathy in Japan: a questionnaire survey. Clin Exp Nephrol. 2023; 27: 1032-1041.
  • Lee M, Suzuki H, Ogiwara K, Aoki R, Kato R, Nakayama M, Fukao Y, Nihei Y, Kano T, Makita Y, Muto M, Yamada K, Suzuki Y.: The nucleotide-sensing Toll-like receptor 9/Toll-like receptor 7 system is a potential therapeutic target for IgA nephropathy. Kidney Int. 2023; 104(5): 943-955.
  • Sakurada T, Io H, et al.: A multi-institutional observational study of outcomes after catheter placement for peritoneal dialysis in Japan. Perit Dial Int. 2023; 43(6): 457-466.
  • Io H, Muto M, Sasaki Y, Ishizaka M, Kano T, Fukuzaki H, Maeda T, Shimizu Y, Nakata J, Suzuki Y.: Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease: a retrospective longitudinal cohort study. BMC Nephrol. 2023; 24(1): 74.
  • Mikami R, Mizutani K, Gohda T, Matsuyama Y, Gotoh H, Nakagawa K, Takemura S, Aoyama N, Matsuura T, Kido D, Takeda K, Saito N, Izumi Y, Iwata T.: Malnutrition-inflammation-atherosclerosis (MIA) syndrome associates with periodontitis in end-stage renal disease patients undergoing hemodialysis: a cross-sectional study. Sci Rep. 2023; 13: 11805.
  • Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T.: The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease. Nephrology (Carlton). 2023; 28: 540-547.
  • Gauckler P, Kesenheimer JS, Geetha D, Odler B, Eller K, Laboux T, Alberici F, Zappa M, Chebotareva N, Moiseev S, Bonilla M, Jhaveri KD, Oniszczuk J, Audard V, Costa D, Mastroianni-Kirsztajn G, Bruchfeld A, Muto M, Windpessl M, Mayer G, Kronbichler A.: COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases. Front Immunol. 2023; 14: 1228457.
  • Nihei Y, Higashiyama M, Miyauchi K, Haniuda K, Suzuki Y, Kubo M, Kitamura D.: Subcutaneous immunization with zymosan generates mucosal IgA-eliciting memory and protects mice from heterologous influenza virus infection. Int Immunol. 2023; 35(8): 377-386.
  • Kawamura T, Hirano K, Koike K, Nishikawa M, Shimizu A, Joh K, Katafuchi R, Hashiguchi A, Matsuzaki K, Maruyama S, Tsuboi N, Narita I, Yano Y, Yokoo T, Suzuki Y.: Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy. Sci Rep. 2023; 13(1): 18455.
  • Murakoshi M, Kamei N, Suzuki Y, Kubota M, Sanuki M, Tashiro H, Iwasawa T, Kato K, Tanaka M, Furuhashi M, Gohda T.: Circulating tumor necrosis factor-related biomarkers predict kidney function decline in Japanese patients with diabetes: an observational cohort study. Diabetes Res Clin Pract. 2023; 206: 111017.
  • Inoshita H, Asaoka D, Matsuno K, Yanagisawa N, Suzuki Y, Miyauchi K.: Cross-sectional study on the association between dietary patterns and sarcopenia in elderly patients with chronic kidney disease receiving conservative treatment. Nutrients. 2023; 15(23): 4994.
  • Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y, Ethnicity and IgA nephropathy: Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023; 16(Suppl 2): 1-8.
2022年 英文原著
  • Fukuzaki H, Nakata J, Nojiri S, Shimizu Y, Kano T, Shirotani Y, Maeda T, Nohara N, Io H, Suzuki Y.: Negative-pressure wound therapy is effective for peritoneal dialysis catheter exit-site management in the early postoperative period. Sci Rep. 2022; 12(1): 70.
  • Zambrano S, He L, Kano T, Sun Y, Charrin E, Lal M, Betsholtz C, Suzuki Y, Patrakka J.: Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 2022; 101(4): 752-765.
  • Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki Y.: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022; 26(4): 316-322.
  • Ishida M, Matsuzaki K, Ikai H, Suzuki H, Kawamura T, Suzuki Y.: Cost analysis of screening for IgA nephropathy using novel biomarkers. Value Health Reg Issues. 2022; 29: 8-15.
  • Sato K, Konta Y, Furuta K, Kamizato K, Furukawa A, Ono A, Ogawa R, Sato R, Endo K, Yamamoto T.: Prognostic factors for acute ischemic stroke in patients undergoing hemodialysis. Clin Exp Nephrol. 2022; 26(3): 286-293.
  • Idei M, Abe M, Tanaka M, Nakata J, Isshiki M, Hino O, Miida T.: Effluent N-terminal expressed in renal cell carcinoma/mesothelin predicts increased peritoneal permeability in patients undergoing peritoneal dialysis. Ther Apher Dial. 2022; 26(5): 1014-1022.
  • Usui N, Uehata A, Nakata J, Inatsu A, Tsubaki A, Saitoh M, Izumi T, Chiba Y, Kojima S, Suzuki Y.: Effect of blood volume change related to intensity of intradialytic aerobic exercise on hemodialysis adequacy: a pilot study. Int Urol Nephrol. 2022; 54(6): 1427-1434.
  • Mikami R, Mizutani K, Matsuyama Y, Gohda T, Gotoh H, Aoyama N, Matsuura T, Kido D, Takeda K, Saito N, Fujiwara T, Izumi Y, Iwata T.: Association of type 2 diabetes with periodontitis and tooth loss in patients undergoing hemodialysis. PLoS One. 2022; 17: e0267494.
  • Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G; JANUS Study Investigators.: Randomized Phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022; 7: 1831-1841.
  • 10. Joh K, Nakazato T, Hashiguchi A, Shimizu A, Katafuchi R, Okonogi H, Koike K, Hirano K, Tsuboi N, Kawamura T, Yokoo T, Narita I, Suzuki Y.: Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy. PLoS One. 2022; 17(9): e0268731.
  • Murakoshi M, Gohda T, Sakuma H, Shibata T, Adachi E, Kishida C, Ichikawa S, Koshida T, Kamei N, Suzuki Y.: Progranulin and its receptor predict kidney function decline in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022; 13: 849457.
  • Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Er L, Reich HN, Barratt J, Cattran DC; International IgA Nephropathy Network.: Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022; 102(1): 160-172.
  • Gohda T, Murakoshi M, Suzuki Y, Hiki M, Naito T, Takahashi K, Tabe Y.: Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients. PLoS One. 2022; 17(10): e0275745.
  • Makita Y, Suzuki H, Nakano D, Yanagawa H, Kano T, Novak J, Nishiyama A, Suzuki Y.: Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. Nephrol Dial Transplant. 2022; 37: 1629-1636.
  • Murakoshi M, Iwasawa T, Koshida T, Suzuki Y, Gohda T, Kato K.: Development of an in-house EphA2 ELISA for human serum and measurement of circulating levels of EphA2 in hypertensive patients with renal dysfunction. Diagnostics (Basel). 2022; 12(12): 3023.
  • Usui N, Nakata J, Uehata A, Ando S, Saitoh M, Kojima S, Inatsu A, Hisadome H, Suzuki Y.: Association of cardiac autonomic neuropathy assessed by heart rate response during exercise with intradialytic hypotension and mortality in hemodialysis patients. Kidney Int. 2022; 101(5): 1054-1062.
  • Kano T, Io H, Nakata J, Sasaki Y, Muto M, Shimizu Y, Fukao Y, Fukuzaki H, Maeda T, Hosoya R, Suzuki Y.: Impact of transferrin saturation and anemia on radial artery calcification in patients with end-stage kidney disease. Nutrients. 2022; 14(20): 4269.
  • Shimizu Y, Wakabayashi K, Nakata J, Io H, Hamada C, Tomino Y, Suzuki Y.: The influence of an unexpected switch of hemodialysis facilities on the quality of life (QOL) in hemodialysis patients. Int J Nephrol Renovasc Dis. 2022; 15: 151-160.
  • Higo M, Shimizu Y, Wakabayashi K, Nakano T, Tomino Y, Suzuki Y.: Post-operative kidney function using deep hypothermic circulatory arrest (DHCA) in aortic arch operation. Int J Nephrol Renovasc Dis. 2022; 15: 239-252.
  • Fukao Y, Suzuki H, Kim JS, Jeong KW, Makita Y, Kano T, Nihei Y, Nakayama M, Lee M, Kato R, Chang JM, Lee SH, Suzuki Y.: Galactose-deficient IgA1 as a candidate urinary marker of IgA nephropathy. J Clin Med. 2022; 11: 3173.
  • Matsuzaki K, Ohigashi T, Sozu T, Ishida M, Kobayashi D, Suzuki H, Suzuki Y, Kawamura T.: Identification of high-risk groups in urinalysis: lessons from the longitudinal analysis of annual check-ups. Healthcare (Basel). 2022; 10: 1704.
  • Ishida M, Matsuzaki K, Suzuki H, Suzuki Y, Kawamura T, Marunaka Y, Iwami T.: Association between 3-year repetitive isolated hematuria and eGFR deterioration in an apparently healthy population: a retrospective cohort study. Int J Environ Res Public Health. 2022; 19: 11466.
  • Nakayama M, Suzuki H, Fukao Y, Lee M, Kano T, Suzuki Y.: Clinical significance of the intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy. Kidney Int Rep. 2022; 7: 2726-2729.
  • Liu L, Khan A, Rodriguez ES, Zanoni F, Li Y, Steers N, Balderes O, Zhang J, Krithivasan P, LeDesma RA, Fischman C, Hebbring SJ, Harley JB, Moncrieffe H, Kottyan LC, Khales BN, Walunas TL, Knevel R, Raychaudhuri S, Karlson EW, Denny JC, Stanaway IB, Crosslin D, Rauen T, Floege J, Eitner F, Moldoveanu Z, Reily C, Knoppova B, Hall S, Sheff JT, Julian BA, Wyatt RJ, Suzuki H, Xie J, Chen N, Zhou X, Zhang H, Hammarström L, Viktorin A, Magnusson PKE, Shang N, Hripcsak G, Weng C, Rundek T, Elkind MSV, Oelsner EC, Barr RG, Ionita-Laza I, Novak J, Gharavi AG, Kiryluk K.: Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Commun. 2022; 13: 6859.
  • Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, Iwasaki M, Fukuda H, Takahara H, Kihara M, Tomita S, Suzuki Y: IgA nephropathy with gross hematuria following a COVID-19 mRNA vaccination. Intern Med. 2022; 61(7): 1033-1037.
  • Mathur M, Barratt J, Suzuki Y, Engler F, Pasetti MF, Yarbrough J, Sloan S, Oldach D: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022; 7(5): 993-1003.
2021年 英文原著
  • Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O'Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J.: Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun. 2021; 118: 102593.
  • Kobayashi T, Ueda S, Takahashi K, Otsuka T, Nagasawa H, Yabuuchi J, Kanaguchi Y, Sugaya T, Urabe T, Tomino Y, Suzuki Y.: Ischemic stroke induces rapid renal oxidative stress and lipometabolic change. Juntendo Med J. 2021; 67(1): 39-45.
  • Honda D, Ohsawa I, Mano S, Rinno H, Tomino Y, Suzuki Y.: Cut-off value of C1-inhibitor function for the diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Intractable Rare Dis Res. 2021; 10: 42-47.
  • Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D; International IgA Nephropathy Network.: Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy. J Am Soc Nephrol. 2021; 32: 436-447.
  • Matsuzaki K, Suzuki H, Kawamura T, Tomino Y, Suzuki Y.: Utility of remission criteria for the renal prognosis of IgA nephropathy. Clin Exp Nephrol. 2021; 25: 988-995.
  • Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y.: Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int. 2021; 100(2): 364-376.
  • Gohda T, Kamei N, Kubota M, Tanaka K, Yamashita Y, Sakuma H, Kishida C, Adachi E, Koshida T, Murakoshi M, Hagiwara S, Funabiki K, Ueda S, Suzuki Y.: Fractional excretion of TNF receptor 1 and 2 in patients with type 2 diabetes and normal renal function. J Diabetes Investig. 2021; 12(3): 382-389.
  • Yang SR, Hua KF, Takahata A, Wu CY, Hsieh CY, Chiu HW, Chen CH, Mukhopadhyay D, Suzuki Y, Ka SM, Huang HS, Chen A.: LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. J Pathol. 2021; 253(4): 427-441.
  • Gohda T, Yanagisawa N, Murakoshi M, Ueda S, Nishizaki Y, Nojiri S, Ohashi Y, Ohno I, Shibagaki Y, Imai N, Iimuro S, Kuwabara M, Hayakawa H, Kimura K, Hosoya T, Suzuki Y.: Association between kidney function decline and baseline TNFR levels or change ratio in TNFR by febuxostat chiefly in non-diabetic CKD patients with asymptomatic hyperuricemia. Front Med. 2021; 8: 634932.
  • 10. Nagasawa H, Ueda S, Otsuka T, Kaifu K, Ono S, Okuma T, Kobayashi T, Matsushita S, Kasai T, Dohi T, Fukushima Y, Amano A, Suzuki Y.: Safety and efficacy of using cereal food (Frugra®) to improve blood pressure and bowel health in patients undergoing chronic hemodialysis: a pilot study. J Pharmacol Sci. 2021; 147(1): 132-137.
  • Fukao Y, Nagasawa H, Nihei Y, Hiki M, Naito T, Kihara M, Gohda T, Ueda S, Suzuki Y.: COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clin Exp Nephrol. 2021; 25(11): 1240-1246.
  • Murakoshi M, Gohda T, Adachi E, Ichikawa S, Hagiwara S, Suzuki Y.: Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice. Sci Rep. 2021; 11: 1194.
  • Mikami R, Mizutani K, Gohda T, Gotoh H, Matsuyama Y, Aoyama N, Matsuura T, Kido D, Takeda K, Izumi Y, Fujiwara T, Iwata T.: Association between circulating TNF receptors and oral bacterium in patients receiving hemodialysis: a cross-sectional study. Clin Exp Nephrol. 2021; 25: 58-65.
  • Usui N, Yokoyama M, Nakata J, Suzuki Y, Tsubaki A, Kojima S, Inatsu A, Hisadome H, Uehata A.: Association between social frailty as well as early physical dysfunction and exercise intolerance among older patients receiving hemodialysis. Geriatr Gerontol Int. 2021; 21: 664-669.
  • Ueno Y, Saito A, Nakata J, Kamagata K, Taniguchi D, Motoi Y, Io H, Andica C, Shindo A, Shiina K, Miyamoto N, Yamashiro K, Urabe T, Suzuki Y, Aoki S, Hattori N.: Possible neuroprotective effects of L-carnitine on white-matter microstructural damage and cognitive decline in hemodialysis patients. Nutrients. 2021; 13: 1292.
  • Akira M, Suzuki H, Ikeda A, Iwasaki M, Honda D, Takahara H, Rinnno H, Tomita S, Suzuki Y.: Atypical histological abnormalities in an adult patient with nephronophthisis harboring NPHP1 deletion. BMC Nephrol. 2021; 22: 261.
  • Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejia-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JSF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J.: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100: 753-779.
2020年 英文原著
  • Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y.: TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020; 97(2): 340-349.
  • Gohda T, Kamei N, Koshida T, Kubota M, Tanaka K, Yamashita Y, Adachi E, Ichikawa S, Murakoshi M, Ueda S, Suzuki Y.: Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. J Diabetes Investig. 2020; 11(2): 435-440.
  • Ichikawa S, Gohda T, Murakoshi M, Li Z, Adachi E, Koshida T, Suzuki Y.: Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice. FEBS Open Bio. 2020; 10(6): 1122-1134.
  • Hara K, Io H, Wakabayashi K, Maeda T, Kanda R, Nakata J, Maeda K, Sengoku H, Machida M, Kojima K, Sakamoto K, Tomino Y, Suzuki Y.: Multicenter laparoscopic evaluation of the peritoneum in peritoneal dialysis patients. Semin Dial. 2020; 33(2): 170-177.
  • Yokoyama H, Yamamoto R, Imai E, Maruyama S, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Furuichi K, Fujimoto K, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.: Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020; 24(10): 893-909.
  • Wu CY, Hua KF, Hsu WH, Suzuki Y, Chu LJ, Lee YC, Takahata A, Lee SL, Wu CC, Nikolic-Paterson DJ, Ka SM, Chen A.: IgA nephropathy benefits from compound K treatment by inhibiting NF-κB/NLRP3 inflammasome and enhancing autophagy and SIRT1. J Immunol. 2020; 205(1): 202-212.
  • Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y.: Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA nephropathy. J Am Soc Nephrol. 2020; 31(9): 2013-2024.
  • Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y.: Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open. 2020; 2(5): e194772.
  • Io H, Nakata J, Inoshita H, Ishizaka M, Tomino Y, Suzuki Y.: Relationship among left ventricular hypertrophy, cardiovascular events, and preferred blood pressure measurement timing in hemodialysis patients. J Clin Med. 2020; 9(11): 3512-3521.
  • Li Z, Murakoshi M, Ichikawa S, Koshida T, Adachi E, Suzuki C, Ueda S, Gohda T, Suzuki Y.: The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice. FEBS Open Bio. 2020; 10(12): 2761-2770.
  • Kubo A, Hidaka T, Nakayama M, Sasaki Y, Takagi M, Suzuki H, Suzuki Y.: Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. BMC Nephrol. 2020; 21(1): 402.
  • Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network.: Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney Int. 2020; 98: 1009-1019.
  • Shimizu Y, Nakata J, Yanagawa N, Shirotani Y, Fukuzaki H, Nohara N, Suzuki Y.: Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Sci Rep. 2020; 10(1): 19638.
  • Yabuuchi J, Ueda S, Yamagishi S, Nohara N, Nagasawa H, Wakabayashi K, Matsui T, Higashimoto Y, Kadoguchi T, Otsuka T, Gohda T, Suzuki Y.: Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. Sci Rep. 2020; 10(1): 17647.
  • Mizutani K, Mikami R, Gohda T, Gotoh H, Aoyama N, Matsuyama Y, Kido D, Takeda K, Izumi Y, Sasaki Y, Iwata T.: Poor oral hygiene and dental caries predict high mortality rate in hemodialysis: a 3-year cohort study. Sci Rep. 2020; 10(1): 21872.
  • Kuwasawa-Iwasaki M, Io H, Muto M, Ichikawa S, Wakabayashi K, Kanda R, Nakata J, Nohara N, Tomino Y, Suzuki Y.: Effects of L-carnitine supplementation in patients receiving hemodialysis or peritoneal dialysis. Nutrients. 2020; 12(11): 3371.
  • Shimizu Y, Nakata J, Maiguma M, Shirotani Y, Fukuzaki H, Nohara N, Io H, Suzuki Y.: Predictive value of 1-week postoperative ultrasonography findings for the patency rate of arteriovenous fistula. Kidney Int Rep. 2020; 5(10): 1746-1752.
  • Nakayama M, Hamada C, Yokoyama K, Tanno Y, Matsuo N, Nakata J, Ishibashi Y, Okuzawa A, Sakamoto K, Nara T, Kakuta T, Nangaku M, Yokoo T, Suzuki Y, Miyata T.: A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. Sci Rep. 2020; 10(1): 17565.
  • Yamada K, Huang Z, Raska M, Reily C, Anderson J, Suzuki H, Kiryluk K, Gharavi AG, Julian BA, Willey CD, Novak J.: Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis. 2020; 6: 168-180.
  • Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, Cui Z, Lin L, Hu X, Yu X, Xu J, Liu G, Caliskan Y, Sidore C, Balderes O, Rosen RJ, Bodria M, Zanoni F, Zhang JY, Krithivasan P, Mehl K, Marasa M, Khan A, Ozay F, Canetta PA, Bomback AS, Appel GB, Sanna-Cherchi S, Sampson MG, Mariani LH, Perkowska-Ptasinska A, Durlik M, Mucha K, Moszczuk B, Foroncewicz B, Pączek L, Habura I, Ars E, Ballarin J, Mani LY, Vogt B, Ozturk S, Yildiz A, Seyahi N, Arikan H, Koc M, Basturk T, Karahan G, Akgul SU, Sever MS, Zhang D, Santoro D, Bonomini M, Londrino F, Gesualdo L, Reiterova J, Tesar V, Izzi C, Savoldi S, Spotti D, Marcantoni C, Messa P, Galliani M, Roccatello D, Granata S, Zaza G, Lugani F, Ghiggeri G, Pisani I, Allegri L, Sprangers B, Park JH, Cho B, Kim YS, Kim DK, Suzuki H, Amoroso A, Cattran DC, Fervenza FC, Pani A, Hamilton P, Harris S, Gupta S, Cheshire C, Dufek S, Issler N, Pepper RJ, Connolly J, Powis S, Bockenhauer D, Stanescu HC, Ashman N, Loos RJF, Kenny EE, Wuttke M, Eckardt KU, Köttgen A, Hofstra JM, Coenen MJH, Kiemeney LA, Akilesh S, Kretzler M, Beck LH, Stengel B, Debiec H, Ronco P, Wetzels JFM, Zoledziewska M, Cucca F, Ionita-Laza I, Lee H, Hoxha E, Stahl RAK, Brenchley P, Scolari F, Zhao MH, Gharavi AG, Kleta R, Chen N, Kiryluk K.: The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020; 11(1): 1600.
2019年 英文原著
  • Honda D, Ohsawa I, Takahashi K, Takahara H, Shoji K, Nagano M, Rinno H, Tomino Y, Suzuki Y.: Significant fluctuations in total complement hemolytic activity as a nutritional parameter after transition from hemodialysis to online hemodiafiltration. Juntendo Med J. 2019; 65(1): 77-84.
  • Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG.: A proliferation-inducing ligand (APRIL)-targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019; 96(1): 104-116.
  • Neufeld M, Molyneux K, Pappelbaum KI, Mayer-Hain S, von Hodenberg C, Ehrchen J, Barratt J, Suzuki Y, Sunderkötter C.: Galactose-deficient IgA1 (Gd-IgA1) in skin and serum from patients with skin-limited and systemic IgA vasculitis. J Am Acad Dermatol. 2019; 81(5): 1078-1085.
  • Tawada M, Hamada C, Suzuki Y, Sakata F, Sun T, Kinashi H, Katsuno T, Takei Y, Maruyama S, Honda K, Mizuno M, Ito Y.: Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients. Clin Exp Nephrol. 2019; 23(5): 689-699.
  • Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC; International IgA Nephropathy Network.: Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179(7): 942-952.
  • Io H, Nakata J, Aoyama R, Inoshita H, Nakano T, Ishizaka M, Fukui M, Tomino Y, Suzuki Y.: Far-infrared therapy for secondary vascular access patency of hemodialysis patients. Ren Replace Ther. 2019.
  • Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J.: Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep. 2019; 4(12): 1717-1724.
  • Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, Nakamura S, Amano H, Hirose S, Yamaji K, Suzuki Y, Tamura N, Miyake S.: A critical role for mucosal-associated invariant T cells as regulators and therapeutic targets in systemic lupus erythematosus. Front Immunol. 2019; 10: 2681.

当講座への入局あるいは大学院進学を希望される方の募集は、随時行っております。
遠慮なく下記へメールまたは電話でお問い合わせください。

医局長：木原　正夫（きはら　まさお）
Tel 03-3813-3111（代表）
メールアドレス：jinnaika@juntendo.ac.jp

入局説明会予定
順天堂医院　後期臨床研修医募集案内